sphenopalatine ganglion
Recently Published Documents


TOTAL DOCUMENTS

453
(FIVE YEARS 155)

H-INDEX

32
(FIVE YEARS 5)

2022 ◽  
Vol 15 (1) ◽  
pp. e243746
Author(s):  
Danielle Levin ◽  
Martin Acquadro ◽  
Joseph Cerasuolo ◽  
Frederic Gerges

A 59-year-old woman underwent an open pancreaticoduodenectomy. Thoracic patient controlled-epidural anaesthesia provided excellent incisional pain relief; however, the patient experienced intractable left shoulder pain (10/10 on the Numerical Rating Scale). To our knowledge, there is no effective established treatment for patients experiencing shoulder pain after an open pancreaticoduodenectomy. The patient’s shoulder pain did not respond to medical management with acetaminophen, ketorolac, lidocaine transdermal patch, oxycodone and hydromorphone. Then, on postoperative day 2, the acute pain service was consulted. Considering that the sphenopalatine ganglion block has been previously reported to be helpful in a number of painful conditions, including shoulder tip pain after thoracic surgery, we offered this treatment to the patient. After just one topical sphenopalatine ganglion block, using a cotton-tipped applicator, the patient’s shoulder pain entirely resolved and did not return. This is the first report of a successful treatment of intractable ipsilateral shoulder pain following an open pancreaticoduodenectomy with transnasal sphenopalatine ganglion block.


2021 ◽  
pp. 915-928
Author(s):  
Parth Shah ◽  
Avinash Pillutla

2021 ◽  
Vol 26 (4) ◽  
pp. 737-741
Author(s):  
Nermin Tepe ◽  
Oktay Faysal Tertemiz

Objective: To assess the effectiveness of sphenopalatine ganglion blockade (SPGB) as an alternative treatment for patients with chronic migraine resistant to medical treatment. Methods: In total, 23 patients with chronic migraine resistant to medical treatment underwent 4 sessions of bilateral transnasal SPGB bi-weekly, and the monthly number of headache days, duration, and numerical rating scale (NRS) response results were recorded. Results: Compared with before SPGB, the frequency of migraine attacks per month (23.66 ± 9.8 vs. 10.5 ± 11.9 days), duration of headaches (31.3 ± 16.8 vs. 18.4 ± 9.8 h), and NRS score (9 ± 0.99 vs. 5.1 ± 2.1) all improved significantly (p < 0.05) eight weeks after intervention. Conclusion: Transnasal SPGB is an alternative to conventional therapy because it benefits patients with chronic migraine resistant to medical treatment, is easy to administer, and has few side effects.


2021 ◽  
Vol 88 (4) ◽  
pp. 291-295
Author(s):  
Suna Akın Takmaz ◽  
Mustafa Karaoğlan ◽  
Bülent Baltacı ◽  
Meltem Bektaş ◽  
Hülya Başar

Sign in / Sign up

Export Citation Format

Share Document